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Factors associated with hyperresponsiveness to adenosine  
5’‐monophosphate in healthy subjects
 LETTER TO THE EDITORTo the editor
Airway hyperresponsiveness (AHR) is used to diagnose asthma. 
AHR can be assessed with a direct (eg, methacholine) or an indirect 
(eg, adenosine 5’‐monophosphate (AMP)) test. Direct tests induce 
airway constriction by stimulating airway smooth muscle contrac‐
tion. Indirect tests provoke mast cells and other inflammatory cells 
to release mediators, that cascade into airway constriction. AHR can 
be defined as the concentration of the stimulus that causes a 20% 
drop in forced expiratory volume in the first second (FEV1)(PC20). 
Although healthy subjects are expected to be unresponsive to AMP,1 
in a group of 108 healthy controls we observed 8 (7.4%) subjects 
with AHR to AMP (PC20AMP ≤160 mg/mL). We therefore investi‐
gated which factors associate with AHR to AMP in these healthy 
subjects.
The NORM database (approved by the ethical committee of our 
hospital, NCT00848406, see Data S1) consists of healthy never or 
current smokers (>10 cigarettes per day). Subjects had no respira‐
tory complaints (ie, cough or dyspnoea) nor any doctor's respiratory 
diagnosis, in the past or present. They presented with normal lung 
function (FEV1 >80%predicted, FEV1/FVC >70%, and <10% increase in 
FEV1%predicted after 400 μg salbutamol) and the absence of AHR to 
methacholine (PC20methacholine >19.8 mg/mL; Table 1). To investi‐
gate which factors associate with AHR to AMP, we compared sub‐
jects with AHR to AMP to those without (≤160 mg/mL vs >160 mg/
mL, Table 1) with a chi‐square or Mann‐Whitney U test. From each 
group of variables, we entered in a multivariate logistic regression 
model the variable which increased the model's adjusted‐R2 most 
(univariate P < 0.01 and mutual Spearman's correlation <|0.7|; 
Table 2, SPSS version 22).
We expected a relation with allergies based on a skin prick test 
(P = 0.59) and self‐reported allergic rhinitis (P = 0.91), but this relation 
was absent. Two samples had sputum eosinophils above the com‐
monly used threshold of 3%. Therefore, we analyzed the percentage 
of sputum eosinophils categorized as <1%, ≥1%, and missing (only 74 
subjects were able to expectorate sputum). AHR was significantly 
associated with sputum eosinophils (Table 1). The multivariate model 
(Table 2) shows that AHR is more likely in subjects with ≥1% sputum 
eosinophils compared to subjects with <1% sputum eosinophils, but 
equally likely in subjects with a missing sputum sample compared to 
those with <1% sputum eosinophils. This indicates that ≥1% sputum 
eosinophils in a healthy subject associates with AHR to AMP. This 
aligns with earlier observations in asthma and allergic rhinitis that 
sputum eosinophils predict AHR to AMP.2 We now show the associ‐
ation in healthy subjects.
Strikingly, all subjects with AHR to AMP were current smokers. 
Smoking status was significantly different (P < 0.01) between sub‐
jects with and without AHR and smokers with AHR smoked more 
cigarettes per day than smokers without AHR (P < 0.01). Previously 
reported healthy subjects with AHR to AMP were also all current 
smokers.3 Furthermore, smoking is associated with AMP sensitiv‐
ity in patients with chronic obstructive pulmonary disease (COPD),3 
as COPD smokers had a significantly lower PC20 AMP compared to 
COPD nonsmokers. Based on these findings, we speculate that AHR 
to AMP in healthy subjects is affected by cigarette smoke‐induced 
presence of mast cells, the primary target for AMP. Cigarette smoke 
irritates epithelial cells, initiating the release of pro‐inflammatory cy‐
tokines.4 These trigger mast cell infiltration and proliferation, result‐
ing in increased numbers of mast cells in the airway's submucosa.5 
Cigarette smoke also causes the reduction of epithelial integrity 
which facilitates the cigarette smoke to reach the mast cells.6 As 
AMP provocation initiates bronchoconstriction through mediators 
released by mast cells,7 healthy smokers may have AHR to AMP.
Next to smoking, AHR to AMP strongly associated with small 
airways function. Univariately, AHR to AMP associated with lower 
forced expiratory flow at 50%, 75%, and 25%‐75% of the forced vital 
capacity (FVC) (FEF50, FEF75, and FEF25‐75, respectively), a higher re‐
sistance in the small airways (difference in resistance to 5 Hz and 
20 Hz (R5‐R20)), and lower lung compliance (increased resonance 
frequency (Fres) and reactance area (AX); all P < 0.03, Table 1). 
Multivariately, small airways function, in terms of R5‐R20, was inde‐
pendently associated with AHR (Table 2). Previously, small airways 
function has been suggested to explain why some patients present 
with respiratory complaints, despite a normal FEV1. It is possible 
that small airways anomalies are already important before respira‐
tory complaints arise, as AHR to AMP might occur earlier than AHR 
to methacholine. Michils et al8 proposed that a discrepancy in the 
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response to methacholine and AMP arises from the different areas 
the provocative agents trigger. They showed that AHR to metha‐
choline originates more centrally in the lungs, where the targets 
for methacholine, the muscarinic receptors, have a higher density. 
By contrast, AHR to AMP originates from the most peripheral lung 
zone (pre‐acinar airways), where in its submucosa mast cells are pre‐
dominantly localized. Involvement of the most peripheral lung zones 
is furthermore indicated by the association between PC20AMP 
≤160 mg/mL and a lower diffusion capacity (TL,CO), in both univariate 
and multivariate analysis (Table 1, 2). Diffusion capacity indirectly 
reflects the small airways via its association with acinar airways dys‐
function (increased Sacin).
9
Finally, AHR to AMP associated with a lower quality of life. 
Univariately, hyperresponsive subjects scored higher on the St. 
George respiratory questionnaire (SGRQ) and asthma and COPD 
control questionnaires (ACQ and CCQ, respectively; Table 1). 
Nevertheless, all scores were below the clinically used thresholds 
of ≤25, ≤1.5, and ≤1, respectively, indicating that our subjects have 
few symptoms. Multivariately, the SGRQ was independently associ‐
ated with AHR to AMP (Table 2) indicating an association with lower 
quality of life. From this, we speculate that AHR to AMP in healthy 
TA B L E  1   Univariate analysis comparing subject with and without airway hyperresponsiveness to AMP
 
AMP > 160 mg/mL 
(n = 100) AMP ≤ 160 mg/mL (n = 8) P‐value
Gender (male‐female) 57‐43 4‐4 7.0 × 10−1
Age (years) 40.50 (22.0; 55.0) 43.00 (25.5; 57.5) 5.4 × 10−1
Positive skin prick test (no‐yes) 66‐34 6‐2 5.9 × 10−1
Allergic rhinitis (self‐reported) (no‐yes) 86‐14 7‐1 9.1 × 10−1
Smoking status (never‐current) 55‐45 0‐8 2.8 × 10−3* 
Packyears (years) 0.3 (0.0; 10.5) 22.55 (7.0; 46.8) 6.0 × 10−4* 
Smokers ‐ Packyears (years) 13.3 (2.9; 25.0) 22.55 (7.0; 46.8) 1.6 × 10−1
Smokers ‐ Equivalent number of cigarettes/day 14.0 (10.0; 18.0) 19.5 (17.3; 23.8) 9.5 × 10−3* 
Blood eosinophils (%) 2.4 (1.4; 3.4) 2.6 (2.0; 5.1) 2.7 × 10−1
Preprovocation sputum eosinophils (categorized) 
(absent (<1%)—present (≥1%)—no sample)
60‐7‐33 3‐4‐1 1.0 × 10−3* 
Preprovocation sputum eosinophils (%)a 0.0 (0.0; 0.4) 1.0 (0.7; 2.9) 2.7 × 10−3* 
FEV1%predicted 109 (101; 114) 100 (90; 110) 7.2 × 10
−2
FEF25%predicted 102 (92; 118) 104 (94; 119) 6.4 × 10
−1
FEV1/FVC (%) 79.33 (76.1; 84.1) 74.98 (71.7; 83.6) 1.5 × 10
−1
R5 (kPa/sL) 0.30 (0.2; 0.4) 0.36 (0.3; 0.5) 9.1 × 10
−2
R20 (kPa/sL) 0.28 (0.2; 0.3) 0.28 (0.2; 0.3) 8.8 × 10
−1
FEF50%predicted 89 (77; 105) 72 (67; 83) 2.3 × 10
−2
FEF75%predicted 73 (59; 94) 52 (42; 64) 7.7 × 10
−3* 
FEF25‐75%predicted 88 (74; 103) 68 (63; 79) 1.1 × 10
−2
R5‐R20 (kPa/sL) 0.02 (0.0; 0.0) 0.11 (0.0; 0.1) 2.7 × 10
−3* 
AX (kPa/L) 0.15 (0.1; 0.2) 0.35 (0.2; 1.1) 2.8 × 10−3* 
Fres (L/s
‐1) 9.77 (8.39; 11.42) 14.91 (10.71; 19.65) 4.8 × 10−3* 
TLCO %predicted 92 (83; 101) 81 (75; 86) 7.4 × 10
−3* 
KCO %predicted 97 (89; 107) 92 (88; 94) 9.9 × 10
−2
COPD Control Questionnaire (CCQ) 0.20 (0.1; 0.4) 0.60 (0.4;1.2) 4.7 × 10−3* 
Asthma Control Questionnaire (ACQ) 0.00 (0.0; 0.0) 0.00 (0.0;0.1) 2.7 × 10−2
St. George Respiratory Questionnaire (SGRQ) 1.93 (1.1; 4.4) 7.65 (2.3; 16.7) 1.0 × 10−2* 
Note: Data are presented as count or median (inter quartile range (IQR)). Binominal data were analyzed with a chi‐square test, while continuous data 
were analyzed with a Mann‐Whitney U test.
Abbreviations: AMP= adenosine 5’‐monophosphate; FEF25, forced expiratory flow at 25% of FVC; FEF50, forced expiratory flow at 50% of FVC; 
FEF75, forced expiratory flow at 75% of FVC; FEF25‐75, forced expiratory flow at 25% to 75% of FVC; R5, resistance to 5 Hz; R20, resistance to 20 Hz; 
R5‐R20, difference in resistance to 5 Hz and 20 Hz; AX, reactance area; Fres, resonance frequency; TLCO, transfer factor for carbon monoxide; Kco, 
TLCO corrected for the alveolar volume; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity.
an = 74, 67 without AHR and 7 with AHR. 
*P ≤ 0.01.
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subjects may be an early predictor for development of pulmonary 
complaints.
In conclusion, in a group of healthy never and current smokers, 
eight subjects (7.4%) expressed AHR to AMP (PC20AMP ≤160 mg/
mL). These subjects were current smokers with a higher cigarette 
consumption compared to subjects without AHR. Furthermore, AHR 
to AMP associated with a reduced small airways function, higher 
sputum eosinophil levels, and a lower quality of life. Further research 
should concentrate on whether AHR to AMP in healthy smokers in‐
dicates the onset of respiratory disease development.
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TA B L E  2   Multivariate logistic regression model predicting 
airway hyperresponsiveness to AMP
 B Standard error P‐value
Equivalent number of 
cigarettes/daya
0.224 0.134 9.6 × 10−2
R5‐R20
b 0.299 0.147 4.1 × 10−2
TLCO %predicted −0.060 0.059 3.1 × 10
−1
Preprovocation sputum eosinophils
Absent(<1%) ‐ ‐ ‐
Present (≥1%) 3.016 1.655 6.8 × 10−2
Missing (no sample) −4.084 3.074 1.8 × 10−1
St. George Respiratory 
Questionnaire (SGRQ)
0.544 0.256 3.4 × 10−2
Note: The logistic regression model was obtained by including the vari‐
able which improved the model's adjusted‐R2 most (univariate P ≤ 0.01 
and mutual Spearman's correlations <|0.7|), from each group of vari‐
ables in Table 1. This model has a Cox & Snellen R2 of 30.4% and 96.3% 
correctly predicted (SPSS version 22).
Abbreviations: R5‐R20, difference in resistance to 5 and 20 Hz; TLCO, 
transfer factor for carbon monoxide.
aBased on all subject (never and current smokers); current and never 
smokers. 
bincorporated in the multivariate regression model on 0.01 scale. 
